429 related articles for article (PubMed ID: 27298396)
1. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
[TBL] [Abstract][Full Text] [Related]
2. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
[TBL] [Abstract][Full Text] [Related]
4. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
[TBL] [Abstract][Full Text] [Related]
5. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
6. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M; Skert C; Borlenghi E; Chiarini M; Cattaneo C; Morello E; Cancelli V; Cattina F; Cerqui E; Pagani C; Passi A; Ribolla R; Bernardi S; Giustini V; Lamorgese C; Ruggeri G; Imberti L; Caimi L; Russo D; Rossi G
Cancer Med; 2016 Feb; 5(2):265-74. PubMed ID: 26715369
[TBL] [Abstract][Full Text] [Related]
7. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.
Ouyang J; Goswami M; Tang G; Peng J; Ravandi F; Daver N; Routbort M; Konoplev S; Lin P; Medeiros LJ; Jorgensen JL; Wang SA
Am J Hematol; 2015 Jun; 90(6):504-10. PubMed ID: 25732229
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
[TBL] [Abstract][Full Text] [Related]
10. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
11. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K
Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635
[TBL] [Abstract][Full Text] [Related]
13. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
16. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
18. The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]